Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology

Sector: Healthcare

Phone: 403-670-7377

Fax: 403-283-0858

Website: oncolyticsbiotech.com

Address:

322 11th Avenue SW, Suite 804, Calgary, Canada

stockinfocuz_ Sep. 13 at 11:23 PM

$ONCY @Oncolytics Biotech CEO Interview | Best Biotech Stocks NASDAQ: ONCY https://youtu.be/zLv8Hk579HI?si=C6yn46b4_6GwILB2

0 · Reply

Fearrr Sep. 12 at 3:18 PM

$ONCY

0 · Reply

StocksPlusStuffers Sep. 12 at 3:17 PM

$ONCY Solid.

0 · Reply

Tunes444 Sep. 12 at 2:24 PM

$ONCY

0 · Reply

Social_Idiot Sep. 12 at 12:39 PM

$ONCY What are the thoughts here? I've been looking at this a few days. This guy seems more like a flipper than a builder. Delisted from Toronto--good. I'm compelled the science but to flip well, you need to be strong financially. They're Canadian and which forms with the SEC show finances? I see only 6-k. Phase 3 was finished a long time ago. Why did this not moved forward? Why are they struggling with so many phase 2 trials?

1 · Reply

stockinfocuz_ Sep. 12 at 11:56 AM

$ONCY Oncolytics Biotech CEO Interview | Best Biotech Stocks NASDAQ: ONCY https://youtu.be/zLv8Hk579HI?si=RItpgdJF9WdMtQ4V

0 · Reply

cbachand Sep. 11 at 5:05 PM

$ONCY https://www.youtube.com/watch?v=zLv8Hk579HI

4 · Reply

DarcyF Sep. 11 at 3:00 PM

$ONCY

0 · Reply

stockinfocuz_ Sep. 11 at 1:24 PM

$ONCY Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors https://finance.yahoo.com/news/oncolytics-biotech-provides-updated-clinical-131000457.html

0 · Reply

Social_Idiot Sep. 10 at 6:24 PM

$ONCY I wondered why tute ownership was so low but I see that they are nowhere near a going concern and are in a serious financial straights position. Leave on my top of watch list for now.

0 · Reply

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 2, 2025, 9:10 AM EDT - 12 days ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Aug 28, 2025, 8:30 AM EDT - 17 days ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 11, 2025, 4:55 PM EDT - 4 weeks ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 8, 2025, 9:05 AM EDT - 5 weeks ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:00 AM EDT - 5 weeks ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 5, 2025, 8:30 AM EDT - 5 weeks ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Jul 29, 2025, 8:30 AM EDT - 6 weeks ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 23, 2025, 9:39 AM EDT - 7 weeks ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 22, 2025, 3:32 PM EDT - 7 weeks ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 16, 2025, 8:30 AM EDT - 2 months ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 10, 2025, 8:30 AM EDT - 2 months ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 8, 2025, 8:30 AM EDT - 2 months ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jun 30, 2025, 7:00 AM EDT - 2 months ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 11, 2025, 7:00 AM EDT - 3 months ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 4 months ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 7:21 PM EDT - 4 months ago

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 4 months ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 4 months ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 5 months ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 5 months ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 5 months ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 11:11 AM EST - 6 months ago

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 7:00 AM EST - 6 months ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Feb 25, 2025, 7:00 AM EST - 7 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 19, 2025, 7:00 AM EST - 7 months ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 18, 2025, 7:00 AM EST - 7 months ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 14, 2025, 5:15 PM EST - 7 months ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 7, 2025, 9:24 PM EST - 7 months ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Jan 22, 2025, 7:00 AM EST - 8 months ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 15, 2025, 7:02 AM EST - 8 months ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Dec 23, 2024, 7:00 AM EST - 9 months ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Dec 18, 2024, 7:00 AM EST - 9 months ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Dec 3, 2024, 7:00 AM EST - 10 months ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Nov 13, 2024, 9:01 PM EST - 10 months ago

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 10 months ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 11, 2024, 7:00 AM EST - 10 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

Aug 1, 2024, 7:55 PM EDT - 1 year ago

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Jun 20, 2024, 7:26 AM EDT - 1 year ago

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

May 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

May 15, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

May 9, 2024, 8:48 PM EDT - 1 year ago

Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript

stockinfocuz_ Sep. 13 at 11:23 PM

$ONCY @Oncolytics Biotech CEO Interview | Best Biotech Stocks NASDAQ: ONCY https://youtu.be/zLv8Hk579HI?si=C6yn46b4_6GwILB2

0 · Reply

Fearrr Sep. 12 at 3:18 PM

$ONCY

0 · Reply

StocksPlusStuffers Sep. 12 at 3:17 PM

$ONCY Solid.

0 · Reply

Tunes444 Sep. 12 at 2:24 PM

$ONCY

0 · Reply

Social_Idiot Sep. 12 at 12:39 PM

1 · Reply

stockinfocuz_ Sep. 12 at 11:56 AM

$ONCY Oncolytics Biotech CEO Interview | Best Biotech Stocks NASDAQ: ONCY https://youtu.be/zLv8Hk579HI?si=RItpgdJF9WdMtQ4V

0 · Reply

cbachand Sep. 11 at 5:05 PM

$ONCY https://www.youtube.com/watch?v=zLv8Hk579HI

4 · Reply

DarcyF Sep. 11 at 3:00 PM

$ONCY

0 · Reply

stockinfocuz_ Sep. 11 at 1:24 PM

0 · Reply

Social_Idiot Sep. 10 at 6:24 PM

$ONCY I wondered why tute ownership was so low but I see that they are nowhere near a going concern and are in a serious financial straights position. Leave on my top of watch list for now.

0 · Reply

Social_Idiot Sep. 10 at 6:17 PM

$ONCY My new ML model pointed to this ticker. Am I wrong? Needs P3 confirmation but the initial review looks like the data is really good.

1 · Reply

Stoness5687 Sep. 10 at 1:01 PM

$ONCY

0 · Reply

ThoughtsOnThis Sep. 10 at 1:01 PM

$ONCY

0 · Reply

Fidely Sep. 10 at 1:00 PM

$ONCY Lets see how the rest of the week plays out and if we get any insights from the HC Wainwright conference.

0 · Reply

Tunes444 Sep. 10 at 12:59 PM

$ONCY good week so far!

0 · Reply

saxy4u Sep. 9 at 7:23 PM

$ONCY well the H.C. Wainwright Global Investment Conference went well today! It’s on tomorrow as well!

1 · Reply

saxy4u Sep. 9 at 7:20 PM

$ONCY 4.3 mill shares! Tutes adding?

1 · Reply

stockinfocuz_ Sep. 9 at 7:15 PM

$ONCY Power hour

0 · Reply

SavedByGraceJC Sep. 9 at 6:10 PM

$ONCY Any chartists out there? When is the next resistance point?

0 · Reply

saxy4u Sep. 9 at 6:08 PM

$ONCY hmmmmm! 3,894,671 shares at 1:43pm 1.365 US

0 · Reply

Tunes444 Sep. 9 at 6:02 PM

$ONCY

0 · Reply

stockinfocuz_ Sep. 9 at 4:32 PM

$ONCY Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market $HCM $CGON $IDYA $CCCC https://barchart.com/share/news/34665959 via @Barchart

0 · Reply

Market Cap	128.46M
Revenue (ttm)	0.00
Net Income (ttm)	-23.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	926,900
Avg Vol	1,188,370
Day's Range	N/A - N/A
Shares Out	100.36M
Stochastic %K	62%
Beta	1.19
Analysts	Strong Sell
Price Target	$4.12